Outcomes Network Graph
Outcomes Flow Chart
Treatment Effectiveness
User reported effectiveness ratings Guaifenesin for various conditions.
| Conditions | Major Improvement | Moderate Improvement | Much Worse | No Effect | Worse | Responses |
|---|---|---|---|---|---|---|
| Neck Pain | 17% | 0% | 8% | 58% | 17% | 12 |
| Chronic Sinusitis | 4% | 35% | 4% | 52% | 4% | 23 |
| Fibromyalgia | 5% | 17% | 7% | 64% | 7% | 123 |
| Throat Clearing | 0% | 27% | 9% | 64% | 0% | 11 |
| Fatigue | 10% | 25% | 8% | 54% | 3% | 118 |
Side Effects
User-reported side effects of Guaifenesin
| Side Effect | Percent of Reports Guaifenesin |
|---|---|
| Allergic to Cymbalta | 19% |
| Extreme Dizziness | 67% |
| Shortness of Breath | 25% |
| Vomiting | 5% |
| Headache | 14% |
| Nausea | 17% |
Outcomes
Below is the degree of change seen after Guaifenesin is higher than average.
|
|
Don't see what you're looking for?
Create a study and help us eradicate suffering!
Daily Distribution
Average by Year
Average by Month
Average by Day of Week
Outcomes Label
Guaifenesin Info
| Property | Value |
|---|---|
| Variable Name | Guaifenesin |
| Aggregation Method | SUM |
| Analysis Performed At | 2020-09-15 |
| Duration of Action | 21 days |
| Filling Value | 0 |
| Kurtosis | 57.549590163934 |
| Maximum Allowed Value | 20 tablets |
| Mean | 0.5083335 tablets |
| Median | 0 tablets |
| Minimum Allowed Value | 0 tablets |
| Number of Aggregate Predictors | 0 |
| Number of Aggregate Outcomes | 10 |
| Number of Measurements | 2 |
| Number of Measurements (including those generated by tagged, joined, or child variables) | 1 |
| Public | true |
| Onset Delay | 30 minutes |
| Standard Deviation | 0.12856816240324 |
| Unit | Tablets |
| User Variables | 2 |
| UPC | 885132679252 |
| Variable Category | Treatments |
| Variable ID | 1333 |
| Variance | 0.016530054644809 |